Startups
-
A Startup’s Flexibility With ADC Cancer Drugs Attracts €128M for Clinical Trials
Tubulis’s next-generation ADC cancer drugs are designed to overcome limitations of currently available therapies in this drug class. The new financing will support clinical trial plans, but first, preclinical proof-of-concept data will be presented during the American Association for Cancer Research annual meeting.
-
Health Tech, MedCitizens, Startups
StartUPDATES: New Developments from Healthcare Startups
Check out news from Band Connect, Fijoya, Team8, and BrainCheck.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Come to MedCity INVEST, Where You Could Meet Your Startup’s First Institutional Investor or a Future Portfolio Company!
The premier boutique healthcare investment conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago
-
StartUPDATES: New developments from healthcare startups
Check out news from Alpha Sophia, Abridge, Baseimmune, Carewell, and Redi Health.
-
Startup Orbis Medicines Launches With €26M for Next-Generation Peptide Drugs
Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.
-
Roots Start to Show for Hair Loss Startup Pelage With a Peek at First Clinical Data
Regenerative medicine startup Pelage Pharmaceuticals has clinical data showing its small molecule activated hair follicle stem cells. GV led a Series A round that funded the UCLA spinout’s Phase 1 clinical trial and will also support Phase 2 testing this year.
-
Lose Fat, Not Muscle: Next Test for Lilly’s Zepbound Pairs It With BioAge Drug
In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.
-
Network With Healthcare Investors at MedCity INVEST 2024!
The conference, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, brings together healthcare investors, startups, and innovative-minded executives. Register today!
-
BioPharma, Devices & Diagnostics, Health Tech, Startups
Healthcare Startups, Time is Running Out to Enter the MedCity INVEST Pitch Perfect Contest in Chicago
Are you a biopharma startup focused on oncology? A devices /diagnostics startup focused on cardiology? Or a health tech startup focused on how consumers/employers
are addressing women’s health? If so, submit an application for MedCity INVEST Pitch Perfect by February 29! -
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
Register for MedCity INVEST in Chicago Where Investors and Healthcare Startups Connect
The conference, scheduled for May 21-22 at the Ritz Carlton in Chicago, is the premier boutique healthcare investment event in the U.S.
-
Connect With More Than 50 Healthcare Startups at MedCity INVEST 2024!
Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!
-
Firefly Bio Unveils $94M to Illuminate the Startup’s New Take on ADC Cancer Meds
Versant Ventures-backed Firefly Bio is part of a growing group of companies developing degrader antibody conjugates, or DACs. These targeted cancer therapies combine properties of antibody drug conjugates and protein degraders in order to overcome limitations of both types of therapies.
-
Network With More Than 50 Healthcare VC firms at MedCity INVEST 2024!
The conference is the premier boutique healthcare investment event in the U.S.
-
This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source
Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.
-
StartUPDATES: New Developments for Healthcare Startups
Check out news from Health Wildcatters, Rivia Health, Apella, and more.